Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network

The commenter is submitting a peer-reviewed study by Tamaki et al. (2024) to support the requested acetaminophen warning. They argue that the study demonstrates unexpectedly high mammary transfer of acetaminophen into breast milk, necessitating expanded warning language for the full perinatal exposure window.

The commenter provides a scientific review from The Journal of Physiology to support a petition regarding prenatal acetaminophen safety. They argue that because acetaminophen readily crosses the placenta and enters the fetal brain, pregnant women should receive clear warning language and informed-consent guidance.

An individual commenter supports the consideration of next-generation analgesic technologies, specifically mentioning SynCore Biotechnology's SNP-810, as a safer alternative to conventional acetaminophen. They argue that products with differentiated metabolic pathways and reduced toxic burden should be evaluated under distinct regulatory frameworks rather than being grouped with legacy products.

The Informed Consent Action Network supports the citizen petition requesting a precautionary warning on prenatal acetaminophen use. They argue that biomarker-based studies provide more reliable evidence of adverse neurodevelopmental outcomes by reducing recall bias and exposure misclassification compared to self-reporting studies.

The Informed Consent Action Network, represented by Siri & Glimstad LLP, supports the proposed action. They argue that a new study on rodent models provides biologically plausible evidence of developmental neurotoxicity from in utero acetaminophen exposure, justifying a precautionary warning during pregnancy.

Americans for Scientific Integrity supports the proposed action by providing supplemental evidence that suggests precautionary risk communication regarding prenatal acetaminophen exposure is appropriate. They argue that recent studies showing structural brain differences and potential risks for ADHD and autism, combined with biological considerations regarding metabolic windows, warrant clearer information for pregnant individuals and clinicians.

Americans for Scientific Integrity (AFSI) argues that the FDA should consolidate the review of two separate petitions regarding acetaminophen safety because the metabolic vulnerabilities of fetuses and infants are biologically continuous. They also request that the FDA mandate a precautionary warning on OTC acetaminophen labels for children due to reported associations with asthma, allergies, and eczema.

The Organization for Latino Health Advocacy opposes the proposed label change for acetaminophen during pregnancy. They argue that the product label should remain based on the full body of scientific and medical literature and emphasize that pregnant patients should not have to suffer unnecessary pain.

LNK International, Inc., a generic pharmaceutical manufacturer, opposes the proposed labeling changes for acetaminophen-containing products. They argue that the current warning statement is sufficient, the proposed changes lack scientific evidence, and that implementing them would be burdensome and confusing for consumers and manufacturers.

A parent expresses concern that acetaminophen (Tylenol) and vaccines may have contributed to their son's autism diagnosis. They support the petition by highlighting their personal experience with medication safety during pregnancy and childhood.